Hani Gabra
BerGenBio ASA · Imperial College London Hammersmith Campus, London, UK
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hani Gabra as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04890509 · A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised PatientsBerGenBio ASA · completed · COVID-19 · study chair
- Ph3NCT01767155 · Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial CancerAEterna Zentaris · completed · Endometrial Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:40 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.J Natl Cancer Inst · 2004471 citationsRCR 10.5
- 205 citationsRCR 13.3
- Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.J Clin Oncol · 2011172 citationsRCR 4.1
- 157 citationsRCR 6.1
- Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.Clin Cancer Res · 2007147 citationsRCR 3.2
- CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.Clin Cancer Res · 2002132 citationsRCR 2.8
- 94 citationsRCR 2.5
- Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.Cancer · 200867 citationsRCR 1.6
- Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.Clin Cancer Res · 201955 citationsRCR 1.9
- 39 citationsRCR 1.0